tradingkey.logo

tradingkey.logo
怜玢


Actuate Therapeutics Inc

ACTU
りォッチリストに远加
0.285USD
-0.011-3.72%
終倀 11-13 16:00ET
15.68M時䟡総額
損倱額盎近12ヶ月PER

Actuate Therapeutics Incに぀いお 䌁業名

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.

Actuate Therapeutics Inc プロフィヌル


䌁業コヌドACTU
䌚瀟名Actuate Therapeutics Inc
䞊堎日Aug 13, 2024
最高経営責任者「CEO」Schmitt (Daniel M)
埓業員数10
蚌刞皮類Ordinary Share
決算期末Aug 13
本瀟所圚地1751 River Run
郜垂FORT WORTH
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号76107
電話番号18479864190
りェブサむトhttps://actuatetherapeutics.com/
䌁業コヌドACTU
䞊堎日Aug 13, 2024
最高経営責任者「CEO」Schmitt (Daniel M)

Actuate Therapeutics Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Daniel M. Schmitt
Mr. Daniel M. Schmitt
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Andrew P. Mazar, Ph.D.
Dr. Andrew P. Mazar, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Aaron G.L. Fletcher, Ph.D.
Dr. Aaron G.L. Fletcher, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Paul Lytle
Mr. Paul Lytle
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Todd Thomson
Mr. Todd Thomson
Independent Director
Independent Director
--
--
Dr. Daniel (Dan) Zabrowski, Ph.D.
Dr. Daniel (Dan) Zabrowski, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jason A. Keyes
Mr. Jason A. Keyes
Independent Director
Independent Director
--
--
Dr. Roger Sawhney, M.D.
Dr. Roger Sawhney, M.D.
Independent Director
Independent Director
--
--
Ms. Amy Lynn Ronneberg
Ms. Amy Lynn Ronneberg
Independent Director
Independent Director
--
--
Dr. Martin H. Huber, M.D.
Dr. Martin H. Huber, M.D.
Independent Director
Independent Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Daniel M. Schmitt
Mr. Daniel M. Schmitt
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Andrew P. Mazar, Ph.D.
Dr. Andrew P. Mazar, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Aaron G.L. Fletcher, Ph.D.
Dr. Aaron G.L. Fletcher, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Paul Lytle
Mr. Paul Lytle
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Todd Thomson
Mr. Todd Thomson
Independent Director
Independent Director
--
--
Dr. Daniel (Dan) Zabrowski, Ph.D.
Dr. Daniel (Dan) Zabrowski, Ph.D.
Independent Director
Independent Director
--
--

よくある質問

Actuate Therapeutics Incの䞊䜍5名の株䞻は誰ですか


Actuate Therapeutics Incの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Daniel M. Schmitt

Actuate Therapeutics IncACTUの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Actuate Therapeutics Incの株匏を保有しおいる機関は100瀟あり、保有株匏の総垂堎䟡倀は玄13.72Mで、党䜓の57.86%を占めおいたす。2025Q4ず比范しお、機関の持ち株は802521.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。